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The relative contribution of the two major breast cancer predis-
posing genes, BRCA1 and BRCA2, differs in breast cancer-only
families and in breast-ovarian cancer families (reviewed in
Rahman and Stratton, 1998). While BRCA1 defects are found in a
majority of high-risk breast-ovarian cancer families, defects in the
second breast cancer predisposition gene, BRCA2 (Wooster et al,
1995) are involved in a large fraction of high-risk families with at
least one case of male breast cancer (Ford et al, 1998). In July
2000, the Breast cancer information core (BIC) reports close to
900 BRCA2 sequence variants, of which about half are truncating
mutations or splicing defects that are likely to determine RNA
instability or protein truncation. These changes are distributed
over the entire coding sequence (10254 nt) and exon–intron
boundaries. 
The aim of this study was threefold: (1) to adapt to BRCA2 a
protocol that allows sensitive and unbiased detection of all types
of mutations using a small number of large amplicons; (2) to
describe the contribution of BRCA2 mutations in French male
breast cancer families; (3) to estimate the contribution of BRCA2
mutations in breast-ovarian cancer families. 
Fluorescence-Assisted Mismatch Analysis (FAMA) (Verpy 
et al, 1994, 1996) was chosen as the most appropriate method for
mutation detection. It relies on detection of mismatches in
heteroduplex DNA which carries strand-specific fluorophores and
allows sensitive detection and precise positioning of mutations
within large amplicons (average size 1.2 kb). Therefore the cost
and time involved in sequencing and in the analysis of sequence
data are strongly reduced. The structure of BRCA2 (Wooster et al,
1995; Tavtigian et al, 1996) lends itself to scanning with large
amplicons, because of the large size of several exons and also
because several clusters of exons can be amplified within large
PCR products, when relatively small introns are present. 
PATIENTS AND METHODS 
Patients 
The BRCA2 gene was screened in two groups of patients. Group 1
consisted of 12 families comprising at least two cases of breast
cancer and at least one affected first-degree male relative. Of these
12 families, 3 also presented one or more ovarian cancer cases.
The mutational status was known in one of the latter families
(IC20, Tavtigian, 1996). Group 2 consisted of 29 breast ovarian
cancer families. The inclusion criteria were: at least one case of
ovarian cancer in a women with a first-degree relative affected by
breast or ovarian cancer. 
All cases reported here were from a consecutive series of
patients ascertained in our genetic counseling sessions at the
Institute Curie, Paris between 1994 and 1997. All 41 index 
cases had been found negative for point mutations or micro-
deletions/insertions upon examination of the BRCA1 gene by
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scanning all exons and exon–intron boundaries using denaturing
gradient gel electrophoresis (DGGE; Stoppa-Lyonnet et al, 1997;
and our unreported data). The probability of being a mutation
carrier at a general autosomal dominant breast cancer suscepti-
bility locus was calculated taking into account all the individual
and familial information and using the parameters of the genetic
model of the Breast Cancer Linkage Consortium study (Easton 
et al, 1993). 
Mutation scanning strategy 
The FAMA scanning primers (Table 1 and Figure 1) were selected
according to the following criteria: 1. amplicons should be in the
1.0 to 1.4 kb range, with overlaps of at least 150 bp, if necessary;
2. the 3¢ end of primers should correspond to a rare sequence. 
To this end, the octamer frequency disparity criterium was used
(Griffais et al, 1991) with the software PC-rare, available from
http://bioinformatics.weizmann.ac.il/pub/software/; 3. chimaeric pri-
mers were designed by extending the 5¢ end of gene-specific
sequences with universal rare 16-mers that differ for the forward
and reverse primers (Table 1). This protocol allows economical
strand-specific end-labelling by using, in a second PCR, a single
universal set of fluorescent primers. Primers used for the 9 small
exons scanned by DGGE are listed in Table 2. 
Polymerase chain reactions for fluorescent chemical
cleavage of mismatch 
250 ng of genomic DNA isolated from peripheral white blood
cells was used for 25 cycles of PCR amplification in a 20 ml reac-
tion with 6 pmoles of chimeric primers. The latter were designed
by extending the gene-specific sequence with ‘universal’ 16-mers,
added to their 5¢ end and differing for the forward and the reverse
primers (see Table 1). PCR conditions were: denaturation at 94˚C
for 5 min followed by 25 cycles at 94˚C for 30 sec, X˚C for 45 sec,
72˚C for 2 min (where X is the annealing temperature given in
Table 1) and final extension at 72˚C for 5 min. Amplitaq (Perkin
Elmer) was used (0.5 units in 25 ml) with standard PCR buffer (1.5
mM MgCl2, 250 uM dNTPs). The fluorescent template was gener-
ated by reamplifying, for 25 cycles, 1 ml of the first amplification
reaction using universal fluorescent primers end-labelled with 
6-FAM & HEX (Perkin-Elmer/ABD), respectively. Heteroduplexes
were formed directly after reamplification, by adding to the PCR
program a denaturation step at 98˚C for 10 min and a renaturation
step at 60˚C for 40 min. Correct amplification was tested on 0.8%
agarose gels. Bichrome PCR fragments were ethanol precipitated
in a dry ice/ethanol bath, upon addition of 60 ug of glycogen
carrier (Boehringer, Mannheim) and resuspended in 18 ml of 
10 mM Tris, pH 8.5. 6 ml of DNA was treated at 37˚C for 30 min
with 20 ml of 7 M hydroxylamine hydrochloride and another
aliquot of 6 ml was incubated for 15 min at 15˚C in 0.4% osmium
tetroxide/2% pyridine/5 mM Hepes, pH 8.0/0.5 mM Na2EDTA 
in a total volume of 25 ml. Aliquots of 7 M hydroxylamine
hydrochloride (Merck) solution, titrated to pH 6.0 by addition of
diethylamine (Fluka), were stored at –80˚C. Osmium tetroxide
(Aldrich, 4% (wt/vol) in water) was diluted in distilled water to
give a 1% stock solution, aliquoted and stored at –80˚C. Mixes
were prepared on ice for the osmium tetroxyde reaction and at
room temperature for the hydroxylamine reaction. Modification
reactions were terminated by transferring the samples to ice and by
adding 200 ml of 0.3 M sodium acetate/0.1 mM Na2EDTA, pH 5.2
and the nucleic acids were ethanol precipitated twice. Pellets were
resuspended in 50 ml of 1 M piperidine (Aldrich) and incubated at
90˚C for 20 min. 5 mg of yeast tRNA and 50 ml of 0.6 M sodium
acetate (pH 6.0) were added, and the nucleic acids were ethanol
precipitated and dried. Pellets were resuspended in 8 ml of a 5/1
mixture of 100% formamide and 25 mM Na2EDTA. 4 mg of each
sample, mixed with 0.5 ml of fluorescent-labelled size standard
(GS2500PROX; Applied Biosystems) were electrophoresed in a
4.25% acrylamide gel in a PE Applied Biosystems 377 DNA
sequencer. Data were analysed using the Genescan™ software. 
Denaturing gradient gel electrophoresis (DGGE) 
50 ng of genomic DNA isolated from peripheral white blood cells
was used for 35 cycles of PCR amplification in a 10 ml reaction
with 3 pmoles of oligonucleotide primers (Table 2). PCR condi-
tions were: denaturation at 94˚C for 5 min followed by 35 cycles at
94˚C for 30 sec, Y˚C for 30 sec, 72˚C for 30 sec (where Y is the
annealing temperature given in Table 2) and final extension at
72˚C for 5 min. To the 5¢ end of one of the primers, a GC-rich
sequence was added as a GC-clamp. Heteroduplexes were formed
directly after the amplification, by denaturation at 98˚C for 10 min
and renaturation in a 98˚C to 25˚C gradient during 40 min. 10 ml of
bromophenol blue/xylene cyanol were added to the PCR products,
and 20 ml were loaded on a DGGE gel. The electrophoresis condi-
tions (for gradient and run time see Table 2) were determined by
use of the Meltmap and SQHTX programs. 
DNA sequencing 
Amplicons revealing the presence of sequence variants were
sequenced using the Big Dye Terminator kit (PE Applied
Biosystems) either entirely (for changes detected by DGGE) or
around the region where the sequence change had been detected
and positioned by FAMA. 
RESULTS 
Mutation detection strategy 
Taking advantage of the large scanning window of the FAMA
method, we have designed primers allowing amplification and
fluorescent labelling of segments larger than 1 kb (Figure 1 and
Table 1). FAMA exploits end-labelling of large amplicons with
strand-specific fluorescent chromophores to determine, upon
chemical cleavage of mismatch, not only the presence of unpaired
or mispaired bases in heteroduplex DNA, but also their precise
location (Verpy et al, 1994, 1996). As shown in Figure 1, exon 11
was divided into 5 amplicons with overlaps of 175 to 299 bp.
Exons 10, 14 and 27 were encompassed each by a large amplicon.
One should note that primers are positioned in introns at an
average distance of 150 bp from the exon boundaries, because the
initial stretch of about 80 bp of the fluorescent cleavage profile
cannot be interpreted with confidence due to background in the
lower portion of the gel. Most other exons were grouped within
large amplicons. Therefore, introns 1, 5, 6, 17, 19, 22 and 23 were
scanned entirely, as shown schematically in Figure 1. 9 small
exons flanked by large intervening sequences, depicted in red in
Figure 1, were modelled for DGGE (Table 2), because of the
proven sensitivity of this method for target DNA in the range of
400 bp. Exon 15 was analysed by FAMA, in spite of its small size484 S Pages et al
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(exon size: 165 bp; FAMA amplicon 509 bp), because it was not
straightforward to find suitable DGGE conditions. Among the
main characteristics of the FAMA method, one should note the
ability to detect multiple changes within large amplicons, thanks to
the limited and controlled nature of the chemical modification
reactions that always result in partial cleavage. Figure 2 shows for
example the profiles obtained for polymorphic sites in the 5¢ end of
the gene (Panel A) and for one of the truncating mutations found in
this study (Panel B). The previously reported polymorphic transi-
tion 203 G®A in exon 2 precedes the translation initiation site.
Panel B of Figure 2 illustrates the use of another large amplicon
that encompasses exon 17, intron 17 and exon 18 and shows a
single nucleotide deletion found in exon 18. The variant alleles
found in this study are summarized in Table 3. The G203A variant
in exon 2 is apparently in linkage disequilibrium with a previously
unreported polymorphic site in intron 1 (+ 421 G®T), since this
association has been observed in 13 individuals. Two additional
previously undescribed polymorphic sites, apparently also in
linkage disequilibrium, were found in intron 1 at positions + 164
and + 222 (Table 3). Among the coding alleles listed in Table 3, the
exon 11 amino acid substitution Asn1147Ser deserves particular
attention. While a contribution to cancer predisposition cannot
be excluded formally, we consider this change as probably 
non-pathogenic because it was found in the index case of family
153, shown below, who has a truncating mutation. 
Male breast cancer families 
12 apparently BRCA1-negative families with at least one case of
male breast cancer were studied. As shown in Table 4, 3 truncating
mutations were found (families 32, 20 and 153). In addition the
missense change Asp2723His was found in family 196. In this
case the BRCA2 status of the son of the index case, who died from
breast cancer, could not be determined because histology slides
were refractory to PCR amplification. 
Based on our finding of 3 truncating mutations and one poten-
tially predisposing missense change, the contribution of BRCA2
mutations to male breast cancer in this particular group of families
appears to be in the 25–35% range. 3 of these 12 male breast cancer
families also had one or more cases of ovarian cancer and two of the
truncating BRCA2 mutations were found in this subset (Table 4). 
Breast-ovarian cancer families 
In addition, 29 breast/ovarian cancer families were studied (Table
4). In these families, 4 truncating BRCA2 mutations were found: 3
Table 1 Primers used for FAMA 
Amplicon Forward primera Reverse primerb Annealing (˚C) Size (bp)c
EX 1–2 5¢ ATTCGGTCAGAACTGACGGTTG 3¢ 5¢GTGGTTAACCTGCAAACGATGAT 3¢ 56 1395 
EX 3 5¢ GTTACACCTTTCTATAGATTCGCAA 3¢ 5¢ CATCGTCTCCATTTTTCGAGTG 3¢ 64 617 
EX 5–6–7 5¢ GAGTTTAAAATACACGGTTTCC 3¢ 5¢ CTACGTTAATCACATCGTACTA 3¢ 56 1027 
EX 10 5¢ AGAAGGGGTGACTGACCGAAA 3¢ 5¢ GAAAAAAACACAGAAGGAATCGTCA 3¢ 66 1391 
EX 11.11 5¢ GCCTCCCAAAAGTGCTGAGATTA 3¢ 5¢ GAAGCTGTTCTGAAGCTACCTCC 3¢ 64 1297 
EX 11.12 5¢ GGTTTATGTTCTTGCAGAGGAG 3¢ 5¢ GCAAGTCCGTTTCATCTTTATGA 3¢ 64 1265 
EX 11.20 5¢ GAAATGACTACTGGCACTTTTGTTG 3¢ 5¢ GTATTTATTCTTTCTGGTTGACCATC 3¢ 62 1262 
EX 11.31 5¢ GAGACTGTGGTGCCACCTAAG 3¢ 5¢ GGAAAAGACTTGCTTGGTACTATC 3¢ 62 1251 
EX 11.32 5¢ GTCTGGATTGGAGAAAGTTTCTA 3¢ 5¢ GTATATCAAACCATACTCCCCCA 3¢ 64 1222 
EX 14 5¢ TATGTGTTATGTGAGGTAGATTG 3¢ 5¢ AACATTAGAATAATTTAAACCTAATC 3¢ 62 834 
EX 15 5¢ GTCTTGAACTCCCGACCTCA 3¢ 5¢ GCAGGCTAATTAGAAAATATGATG 3¢ 62 509 
EX 17–18 5¢ CAAAATGCTGGGAGTATAGGC 3¢ 5¢ GAAATTGAGCATCCTTAGTAAGC 3¢ 58 1383 
EX 19–20 5¢ TTACTTATTTACTGTCTTACTAATC 3¢ 5¢ CAAAAAAGAATACCCTAGATACTAA 3¢ 62 1037 
EX 22–23–24 5¢ GAATATTATGTGAGAAACTGATTAC 3¢ 5¢ TTACTTTCAGATCACTAGTTAGC 3¢ 62 1142 
EX 27 5¢ TGAACTGAAATCACCTAACCTATTA 3¢ 5¢ TGAAGCAAAAGTATACCAATACGG 3¢ 62 990 
aUniversal extension: 5¢TAGTCGACGACCGTTA3¢. Fluorescent primer: 5¢-BFAMggTAGTCGACGACCGTTA-3¢. bUniversal extension: 5¢TCGGATAGCTAGTCGT3¢.
Fluorescent primer: 5¢-(HEX)ggTCGGATAGCTAGTCGT-3¢. cIncluding extensions. 
Table 2 Primers and DGGE conditions 
Amplicon Forward primer Reverse primer Annealing Size  Gradient Migration
(˚C) (bp) (%) (h) 
EX 4 5¢ F(GC) CATTCTCATTCCCAGTATAGAGG 3¢ 5¢ AGATCTTCTACCAGGCTCTTAGC 3¢ 58 340 20–70 4 
EX 8 5¢ F(GC) GATTGACCTTTCTAATTACTATAC 3¢ 5¢ AAATAATTTAACAAGGCATTCC 3¢ 50 344 20–70 2 
EX 9 5¢ F(GC) GGACCTAGGTTGATTGCAGATAAC 3¢ 5¢ CGGTAAACTGAGATCACGGGTGACA 3¢ 65 390 20–70 2 
EX 12 5¢ F(GC) GGTCTATAGACTTTTGAGAA 3¢ 5¢ GTCAGAATATTATATACCCATACC 3¢ 50 293 10–60 2 
EX 13 5¢ CAGTAACATGGATATTCTCTTAG 3¢ 5¢ R(GC) AGTGTCATTATTTTTAGAAATGTTC 3¢ 58 274 10–60 2 
EX 16 5¢ F(GC) GTGTGATACATGTTTACTTTAAATTG 3¢ 5¢ GTTCGAGAGACAGTTAAGAGAAG 3¢ 62 404 20–70 2 
EX 21 5¢ GGGTGTTTTATGCTTGGTTCTTT 3¢ 5¢ R(GC) ATGGCCAGAGAGTTAAAACAGC 3¢ 62 334 20–70 3 
30–80 8 
EX 25 5¢ F(GC) CTTGCATCTTAAAATTCATCTAAC 3¢ 5¢ GATACTGGACTGTCAAAATAG 3¢ 52 434 20–70 5 
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in exon 11 (families 946, 1063 and 1332) and one in exon 23
(family 1006). Thus, a total of 6 truncating mutations were found
in 32 breast-ovarian cancer families, including the two mutations
found in families with male breast cancer cases. 3 of these 6 muta-
tions were within the region of exon 11 defined as OCCR (ovarian
cancer cluster region) by Gaither et al (1997). 
As the calculated probabilities of being a mutation carrier varied
considerably (Table 4), we examined the distribution of the muta-
tions found according to the level of predisposition probability.
Note that the calculation of predisposition probabilities (see the
Patients and Methods section) takes into account the whole family
history, including number of cases, pedigree distribution, age of
disease onset and current age of unaffected relatives. Only 2 of the
8 truncating mutations were found in patients with probabilities
lower than 95% (one in a male breast cancer patient and one in the
breast-ovarian cancer group). Conversely, 5 of the 16 apparently
BRCA1-negative index cases with predisposition probabilities of
95% or more had truncating mutations in BRCA2. 
DISCUSSION 
The mutation scanning strategy described here for BRCA2 (Figure 1)
covers all exons and large segments of the intron sequences and is
based on the use of a small number of amplicons (i.e. 15 large
amplicons scanned with FAMA and 9 small amplicons scanned
with DGGE, see Figure 1). This protocol does not require expen-
sive reagents nor specialized equipment in addition to a DNA
sequencer. Moreover, FAMA reduces substantially the number of
sequencing reactions, thanks to the precise information about the
position of the nucleotide change. All mutations and sequence
variants reported in this study (Tables 3 and 4) were found in the
regions scanned by FAMA. This result was not surprising, because
FAMA covered more than 80% of the coding sequences and two-
thirds of the splice site junctions, corresponding to a total of 15 kb
of the BRCA2 sequence, while only 3 kb were scanned by DGGE. 
A global assessment of the sensitivity of this approach with
regard to point mutations is provided by our ability to detect a
large number of single nucleotide polymorphisms, as shown in
Table 3. In fact, all 9 exonic single nucleotide polymorphisms that
have been reported by Wagner et al (1999) with global heterozy-
gosity of at least 0.1 were detected in this relatively small sample
of 41 unrelated patients (Table 3). 3 frequent intronic polymorphic
changes described in that study (introns 11, 14 and 20) have 
not been found in this work because our primer design in 
these regions was not aimed at ensuring detection of sequence
changes at distances larger than 50 bp from the exon boundaries
(see Figure 1). Conversely, as shown in Table 3, we found unre-
ported polymorphic sites in intron 1 (positions 189 + 421, 189 +
222 and 189 + 164) in exon 11 (positions 4266 and 3668) in intron
22 (position 9181 + 135) and in exon 27 (positions 10589 and
10591). 
As the combination of methods used here affords high sensi-
tivity of detection, not only for frameshifts but also for single
Figure 1 Design of amplicons. (A) Schematic representation of the 27
exons of BRCA2 (on scale). (B) Amplicons and extent of intron sequences
scanned (amplicon sizes are listed in Tables 1 and 2). Regions scanned by
FAMA and by DGGE are shown in green and red, respectively. The distance
of the FAMA fluorophore from exon boundaries was in each case at least
150 bp. Within exon 11, amplicons 1111, 1112, 1120, 1131 and 1132
overlapped by 198, 175, 299, and 229 bp (from left to right) 
Table 3 Observed variants in BRCA2
Exon/intron Nucleotide Codon Nucleotide change  Amino acid change Observed heterozygotes (%) BIC report 
Intron 1 IVS + 421 – G>T non-coding  13/82 (16) 13 (32) No 
Intron 1 IVS1 + 222 – C>T non-coding  12/82 (15) 12 (29) No 
Intron 1 IVS1 + 164 – A>G non-coding  12/82 (15) 12 (29) No 
Exon 2 203 – G>A non-coding 13/82 (16) 13 (32)  Yes 
Exon 10a 1093 289 A>C Asn>His 1/82 (1) 1 (2) Yes 
Exon 10 1342 372 A>C His>Asn 15/82 (18) 15 (36) Yes 
Exon 10 1593 455 A>G Ser (Silent) 1/82 (1) 1 (2) Yes 
Exon 11 2457 743 T>C His (Silent) 2/82 (2) 2 (4) Yes 
Exon 11a 3199 991 A>G Asn>Asp 2/82 (2) 2 (4) Yes 
Exon 11 3624 1132 A>G Lys (Silent) 2/82 (2) 2 (4) Yes 
Exon 11b 3668 1147 A>G Asn>Ser 1/82 (1) 1  (2) No 
Exon 11 4035 1269 T>C Val (Silent) 6/82 (7) 6 (14) Yes 
Exon 11 4266 1346 T>C Thr (Silent) 1/82 (1) 1 (2) No 
Exon 11 5972 1915 C>T Thr>Met 3/82 (4) 3 (7) Yes 
Exon 14 7470 2414 A>G Ser (Silent) 1/82 (1) 1 (2) Yes 
Intron 22 IVS22 + 135 – C>G non-coding 1/82 (1) 1 (2) No 
Intron 26 IVS26 – 20 – C>T non-coding  1/82 (1) 1 (2) No 
Exon 27 10589 – A>C non-coding 4/82 (5) 4 (10) No 
Exon 27 10591 – A>C non-coding 5/82 (6) 5 (12) No 
aIn one patient (F196) Asn289His (exon 10) and Asn991Asp (exon 11) were found together with Asp2723His (cf Table 4). bAsn1147Ser was found in the index
case of family 153, who has a truncating mutation (cf Table 4). 486 S Pages et al
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nucleotide substitutions, these data strengthen the notion that
truncating mutations, mainly due to frameshifts, represent the
largest fraction of BRCA2 mutations. However we found a large
number of sequence variants resulting from point mutations and a
potentially pathogenic missense change (Asp2723His in exon 18
of family 196; Table 4). This missense change has been reported 7
times in the BIC database as an uncharacterized variant, but has
not been found in normal controls nor in a recent study of individ-
uals from world-wide populations (Wagner, 1999). In this study it
was found in the index case of a family with 2 male breast cancer
cases, but other family members were not available for further
studies. This amino acid substitution differs from the 5 ones, 
listed as coding variants in Table 3, that have been found either in
normal individuals (Wagner et al, 1999) or in a patient carrying 
the truncating mutation 8222delA (Asn1147Ser found in family
153; see Table 4). As shown in Figure 3, Asp2723 is a conserved
amino acid and the amino acid sequence encoded by exon 18
(residues 2659–2778) is also highly conserved. Moreover, the
fragment of BRCA2 between amino acids 2472 and 2957 has 77%
identity between mouse and man (compared with 59% overall) and
is the site of an interaction with the product of the DSS1 gene
(Marston et al, 1999). This region is distinct from the regions of
interaction of BRCA2 with RAD51 as well as from the position of
the nuclear localization signal (Welcsh et al, 2000). Based on these
observations, the amino acid substitution Asp2723His might
contribute to cancer predisposition and its effect on functional
interactions of the BRCA2 protein should be investigated. It is of
interest to note that this change was found in the index case of
Table 4 BRCA2 mutation screening in 41 families (including 12 with male breast cancers) 
Familial cancersa BRCA2 mutations 
BCs Index case Nucleotide Aminoacid 
Familyb,d M F OC B/OC Sex PP (%)c Exon change change 
32 1 1 – M 43 10 1529del4 ter460 
154 1 1 – M 65 
196 2 – – M 93 18 G8395C Asp2723His 
344 1 3 – M 54 
392 1 3 – F 93 
415 1 2 – F 89 
423 1 2 – M 87 
469 1 2 – F 93 
738 1 1 – M 74 
20 2 6 2 M 98 18 8525delC ter2776 
153 1 10 1 F 96 18 8222delA ter2676 
503 1 5 1 M 96 
16 – 3 1 F 97 
51 – 2 – 1 F 90 
301 – 1 2 F 85 
557 – – 1 1 F 90 
659 – 5 1 F 95 
707 – 4 1 F 98 
827 – 1 2 F 96 
842 – 2 2 F 96 
887 – 3 1 F 90 
901 – 3 – 1 F 80 
902 – 2 1 F 97 
946 – 3 1 F 93 11 3970del4 ter1258 
964 – 1 1 F 33 
1006 – 2 1 F 97 23 9254del5 ter3016 
1063 – 5 1 F 96 11 C5873A ser1882ter 
1079 – 3 1 F 76 
1083 – 3 1 F 85 
1084 – 2 1 F 93 
1092 – 3 1 F 92 
1109 – 2 3 F 96 
1139 – 1 1 F 49 
1158 – 2 1 F 96 
1165 – 1 2 F 98 
1182 – 3 1 F 96 
1208 – 1 1 F 10 
1244 – 2 1 F 67 
1245 – 3 1 F 85 
1332 – 6 1 F 95 11 5579delA ter1785 
1389 – 4 4 F 77e
aFamilial cancers: BC, breast cancer; M, male; F, female; OC, ovarian cancer; B/OC, breast/ovarian cancer. bThe first twelve families have at
least one case of male breast cancer. cPP, predisposition probability of the index case. dUnderlined numbers denote families in which the index
case had a predisposition probability of at least 95%. eLow predisposition probability because the 4 ovarian cancer cases belong to 3 different
parental lineages. Fluorescence-assisted mismatch analysis of BRCA2 487
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family 196 together with two rare variants (Asn289His and Asn991
Asp). The former of these polymorphisms showed a significant
deficit of heterozygosity in patients (Wagner et al, 1999). While the
phase of these allelic variants could not be investigated for lack of
family members, it is tempting to speculate that associations of rare
alleles of BRCA2 may sometimes result in increased predisposition
to cancer. Thus, the nature of missense changes in general and in
particular the effects resulting from combinations of missense
changes deserve more attention also in view of the potential
insights they might provide into BRCA2 function. 
The contribution of BRCA2 mutations in male breast cancer
families was found to be 3/12 (25%) or 4/12 (33.3%) depending on
the inclusion or not of the missense change Asp2723His. One of
the truncating mutations was found in a family (number 32), which
is characterized by only one case of male breast cancer and one
case of female breast cancer and by a low predisposition proba-
bility (43%) of the index case. These observations suggest that the
BRCA2 gene should be screened with priority in male breast
cancer families, including those with small numbers of breast
cancer cases. It is also interesting to note that 2 truncating BRCA2
mutations were found in the subgroup of 3 families with one or
more cases of ovarian cancer in addition to male breast cancers
(families 20 and 153 in Table 4). Our data are consistent with
recent estimates of a major contribution of BRCA2 mutations to
breast cancer predisposition when at least one first-degree male
relative is affected (76% in high risk families, according to Ford,
1998). On the other hand no BRCA1 mutation was found in this
group, in agreement with the low contribution of BRCA1 to male
breast cancer (Ford, 1998), although exon deletions or duplica-
tions of BRCA1 cannot be ruled out (discussed below). 
Concerning our original cohort of 59 breast ovarian cancer
families, 23 truncating mutations and 4 additional likely delete-
rious missense mutations had been found in BRCA1 (Stoppa-
Lyonnet et al, 1997; and our unreported data). The contribution of
detectable BRCA1 mutations to this group was estimated at 46%
(95% CI 33–59). It is however likely that several of the apparently
BRCA1- and BRCA2-negative patients listed in Table 4 in fact had
a partial BRCA1 deletion or duplication. Screening of these
patients for exon deletions or duplications is underway and a
BRCA1 rearrangement has for example been found in family 827
of Table 2 (Gad et al, in press). Recent studies have suggested that
the frequency of BRCA1 genomic rearrangements in families with
breast-ovarian cancer may be equal or even greater than that of
BRCA2 mutations in coding regions (Unger et al, 2000). The 6
BRCA2 mutations observed in this study in breast-ovarian cancer
families, including 3 families in which one or more first-degree
male relative(s) had breast cancer, indicate a BRCA2 contribution
of 10% (95% CI 2.5–17.5) to our original group of 59 breast-
ovarian cancer families. 
Figure 3 Conservation across species of the Asp2723His change found in
family 196. The amino acid sequence deduced from exon 18 is shown for
man (Tavtigian et al, 1996), mouse (Sharan et al, 1997) and rat (McAllister 
et al, 1997; Genebank, accession number: NM 009765). Amino acids with
similarity scores of >0.5 according to the GCG BESTFIT program are shown
with double dots. Those with similarities <0.5 are shown with single dots. The
Asp to His substitution, found in this patient, belongs to the latter group.
Mouse residues 2605 and 2648 (both underlined) are identical to the
corresponding human residues in another published mouse sequence
(Connor et al, 1997) 
Figure 2 Examples of fluorescent chemical cleavage profiles (both on antisense strands) obtained from large amplicons. (Panel A) Region containing exon 1,
intron 1 and exon 2; total length of uncleaved DNA is 1402 nt. Peaks at 276 nt (G203A) and at 617 nt (G/T+421 int1) from the HEX fluorophore on the lower
strand are observed in the C-specific (hydroxylamine, HA) reaction. (Panel B) Amplicon containing exon 17, intron 17 and exon 18. The mutation found in exon
18 is shown. An unpaired T in the noncoding strand gives rise to a cleavage peak at 397 nt from the HEX fluorophore in the T-specific reaction (osmium
tetroxide, OT). Profiles shown in red in each panel represent the same strand of control samples subjected to the same CCM reaction and run on the same gel 488 S Pages et al
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